CRCbioscreen
next generation colorectal cancer screening

Colorectal cancer (CRC) is one of the most common cancer types world wide, with about 1.8 million new cases and 0.9 million people dying from the disease annually

Early detection and removal ("screening") is the most effective approach for beating this disease, and the

widely used Faecal Immunochemical Test (FIT) currently is the most cost effective method for this purpose

CRCbioscreen is developing a novel, multi-target Faecal Immunochemical Test (mt FIT), which has improved sensitivity for high risk precursor lesions, while maintaining the same low level of false postives as the current FIT has


Contact

CRCbioscreen BV
Health & Innovation District (Hid)
Plesmanlaan 125
1066 CX Amsterdam

info@crcbioscreen.com

Our company

CRCbioscreen was founded in 2021 as a spin off company from the Netherlands Cancer Institute. The company holds an exclusive license on the intellectual property of NKI's Translational Gastrointestinal Oncology group regarding a stool based screening test directed against a combination of proteins has the potential to increase sensitivity for high risk precursor lesions of colorectal cancer

 

 
 
 
 
E-mailen
LinkedIn